MedDataX Logo

The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis

NCT ID: NCT02627209

Last Updated: 2015-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the significance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with ocular involvement of other autoimmune inflammatory and infectious diseases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Increased serum levels of angiotensin converting enzyme and lysozyme are considered as inflammatory markers for diagnosis of sarcoidosis which is an autoimmune inflammatory disease. Sarcoidosis, ankylosing spondylitis and Behcet's disease are the most common autoimmune inflammatory diseases involving the eye.

Elevated serum angiotensin converting enzyme levels have also been reported in tuberculosis. Syphilis and tuberculosis are the most common infectious diseases involving the eye.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis Tuberculosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Angiotensin converting enzyme Lysozyme Ankylosing spondylitis Behcet's disease Sarcoidosis Syphilis Tuberculosis Ocular inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

serum angiotensin converting enzyme

spectrophotometric assay

Group Type ACTIVE_COMPARATOR

spectrophotometric assay

Intervention Type OTHER

measurement of enzyme activity in the serum

radial immunodiffusion

Intervention Type OTHER

measurement of the precipitated ring diameters showing enzyme activity in the serum

serum lysozyme

radial immunodiffusion

Group Type ACTIVE_COMPARATOR

spectrophotometric assay

Intervention Type OTHER

measurement of enzyme activity in the serum

radial immunodiffusion

Intervention Type OTHER

measurement of the precipitated ring diameters showing enzyme activity in the serum

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

spectrophotometric assay

measurement of enzyme activity in the serum

Intervention Type OTHER

radial immunodiffusion

measurement of the precipitated ring diameters showing enzyme activity in the serum

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects have ocular inflammation diagnosed as sarcoidosis, ankylosing spondylitis, behcet's disease
* Subjects have ocular infection diagnosed as tuberculosis and syphilis
* Subjects have refractive errors only

Exclusion Criteria

* Subjects using ACE inhibitors, systemic steroids, immunosuppressive or immunomodulatory therapies
Minimum Eligible Age

9 Years

Maximum Eligible Age

86 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ozlem Sahin

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ozlem Sahin

Medical Doctor, Specialist in Ophthalmology, Uveitis and Ocular Immunology

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ioannis Pallikaris, MD

Role: STUDY_CHAIR

DunyaGoz Hospital, Etiler, yanarsu sokak no.1 besiktaş Istanbul Turkey

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

DunyaGoz hospital Tunus caddesi no.28 kavaklidere

Çankaya, Ankara, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ozlem sahin, MD

Role: CONTACT

Phone: 90-537-5523064

Email: [email protected]

Eda Karaismailoglu, MS

Role: CONTACT

Phone: 90-533-3097848

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ozlem sahin, MD

Role: primary

eda karaismailoğlu, MS

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Birnbaum AD, Oh FS, Chakrabarti A, Tessler HH, Goldstein DA. Clinical features and diagnostic evaluation of biopsy-proven ocular sarcoidosis. Arch Ophthalmol. 2011 Apr;129(4):409-13. doi: 10.1001/archophthalmol.2011.52.

Reference Type RESULT
PMID: 21482866 (View on PubMed)

Sen DK, Sarin GS. Immunoassay of serum muramidase (lysozyme) in ocular diseases. Indian J Ophthalmol. 1987;35(5-6):103-7.

Reference Type RESULT
PMID: 3508756 (View on PubMed)

Sahin O, Ziaei A, Karaismailoglu E, Taheri N. The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases. BMC Ophthalmol. 2016 Feb 16;16:19. doi: 10.1186/s12886-016-0194-4.

Reference Type DERIVED
PMID: 26879979 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DGH-070

Identifier Type: -

Identifier Source: org_study_id